You probably know someone who has worried about forgetfulness in a parent or in themselves.
Most of us hope a quick visit to the doctor can settle whether it's normal aging or something more. A short in-office test is usually the first step.
A team at Boston University is making the case that this quick check is no longer enough.
In a Boston University announcement by EurekAlert, researchers described findings published in the Journal Neurology Open Access.
Also read: 70% of women with PCOS may not know they have it: Here are the symptoms
A longer, one-hour assessment picked up memory problems a widely used short test had missed.
The tool is called the Neurobehavioral Status Exam, or NBSE.
It takes about an hour and covers memory, attention, language, reasoning, and mood.
The researchers reviewed records from 1,858 veterans tested at a Veterans Affairs memory clinic between 2017 and 2025.
Also read: Doctors warn: Hard runs in cold weather can strain even a healthy heart
What the longer test catches that brief screeners miss
Among veterans who scored in the "normal" range on the Montreal Cognitive Assessment, a widely used short screener, the longer NBSE flagged mild cognitive impairment in 40 percent of them.
Nearly 9 percent also met criteria for dementia.
The one-hour test picked up previously undetected depression or anxiety symptoms in about 30 percent of patients, too.
Those conditions can mimic memory loss and often need their own treatment.
Also read: Turning the clocks back does not give you a full hour of extra sleep, study finds
Brandon Frank, assistant professor of neurology at Boston University Chobanian & Avedisian School of Medicine, told the university that brief screens remain useful but can miss important problems.
A longer, more comprehensive check can give a clearer picture when someone notices changes in memory or daily life, he said.
Why staging matters now for Alzheimer's treatment
Until recently, a cognitive diagnosis mostly guided counseling and support. That has changed.
The FDA has fully approved two disease-modifying drugs for early Alzheimer's. One is lecanemab, a monoclonal antibody sold as Leqembi by Eisai.
Also read: One injection could change how we treat fatty liver disease
The other is donanemab, sold as Kisunla by Eli Lilly.
Both drugs are approved only for a narrow window.
They are meant for people with mild cognitive impairment (MCI) or mild dementia caused by Alzheimer's.
Brain scans or spinal fluid tests must also confirm amyloid plaque buildup, per the Alzheimer's Association.
Also read: Your packaged food label may be hiding how unhealthy the product really is
Doctors who cannot tell whether a patient is still at MCI, already in mild dementia, or beyond it cannot send them for treatment.
Staging has moved from a mostly academic exercise to a gatekeeper for access to the first drugs that can actually slow the disease.
The one-hour test is a proposal not a standard
The Boston team is not saying every clinic must switch tomorrow.
The paper frames the NBSE as a practical option that fits into an hour, works in person or by video, and gives neurologists a staging picture that current brief tools often cannot.
For now it remains a research proposal rather than an adopted guideline.
Anyone who has noticed persistent changes in memory, language, or daily tasks should raise it with their doctor.
The newer therapies only help when Alzheimer's is caught in its earliest stages, which is exactly the window the quick in-office screen can miss.
This article is made and published by Ida-Marie Palm Varbæk, who may have used AI in the preparation.
